Matching articles for "baricitinib"
Issue 1749 · March 2, 2026
Drugs for Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2026 Mar 2; 68(1749):33-40 doi:10.58347/tml.2026.1749a
Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into or first appearing in adulthood or even old age. Guidelines for the treatment of AD have recently been updated.
Issue 1740 · October 27, 2025
Deuruxolitinib (Leqselvi) for Severe Alopecia Areata

The FDA has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib ( Leqselvi – Sun) for treatment of severe alopecia areata in adults. Two other oral JAK inhibitors are approved for treatment of…

Med Lett Drugs Ther. 2025 Oct 27; 67(1740):174-6 doi:10.58347/tml.2025.1740b
The FDA has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib ( Leqselvi – Sun) for treatment of severe alopecia areata in adults. Two other oral JAK inhibitors are approved for treatment of severe alopecia areata: baricitinib (Olumiant) is approved for use in adults, and ritlecitinib (Litfulo) is approved for use in patients ≥12 years old.
Issue 1722 · February 17, 2025
Nemolizumab (Nemluvio) for Atopic Dermatitis

Nemolizumab ( Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin…

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):25-7 doi:10.58347/tml.2025.1722a
Nemolizumab ( Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical prescription drugs. It is the first IL-31 receptor antagonist to be approved in the US for this indication. Nemolizumab was approved earlier for treatment of prurigo nodularis in adults.
Issue 1715 · November 11, 2024
Lebrikizumab (Ebglyss) for Atopic Dermatitis

The FDA has approved lebrikizumab-lbkz ( Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):179-81 doi:10.58347/tml.2024.1715b
The FDA has approved lebrikizumab-lbkz ( Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated with topical therapy in patients ≥12 years old (weight ≥40 kg). Lebrikizumab is the third subcutaneously injected human IgG4 monoclonal antibody to be approved in the US for this indication. Tralokinumab (Adbry) , another IL-13 antagonist, is also approved for use in patients ≥12 years old, and dupilumab (Dupixent) , an IL-4 and IL-13 inhibitor, is approved for use in patients ≥6 months old.
Issue 1690 · November 27, 2023
Ritlecitinib (Litfulo) for Severe Alopecia Areata

The FDA has approved ritlecitinib ( Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug…

Med Lett Drugs Ther. 2023 Nov 27; 65(1690):185-6 doi:10.58347/tml.2023.1690a
The FDA has approved ritlecitinib ( Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug to be approved in the US for treatment of severe alopecia areata; baricitinib (Olumiant) , a JAK inhibitor, is approved only for use in adults.
Issue 1677 · May 29, 2023 Free
COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19

The investigational anti-complement component 5a (C5a) antibody vilobelimab ( Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with…

Med Lett Drugs Ther. 2023 May 29; 65(1677):86-7 doi:10.58347/tml.2023.1677d
The investigational anti-complement component 5a (C5a) antibody vilobelimab ( Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with COVID-19 beginning within 48 hours after invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) is started. Vilobelimab is the first anti-C5a antibody to become available in the US.
Issue 1667 · January 9, 2023 Free
COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)

The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has been approved by the FDA for IV treatment of COVID-19 in hospitalized adults who are receiving a systemic corticosteroid…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):e9 doi:10.58347/tml.2023.1667d
The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has been approved by the FDA for IV treatment of COVID-19 in hospitalized adults who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for treatment of children 2-17 years old who are hospitalized with COVID-19 and require oxygen support.
Issue 1665 · December 12, 2022 Free
An EUA for Anakinra (Kineret) for COVID-19 (online only)

The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19…

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e203-4
The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19 pneumonia who require low- or high-flow supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have elevated plasma levels of soluble urokinase plasminogen activator receptor (suPAR). Anakinra has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis. Assays for suPAR are not commercially available in the US.
Issue 1658 · September 5, 2022
Baricitinib (Olumiant) for Severe Alopecia Areata

The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):139-41
The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19 in certain hospitalized adults, has now been approved for treatment of severe alopecia areata in adults. Baricitinib is the first systemic treatment to be approved in the US for this indication.
Issue 1652 · June 13, 2022 Free
COVID-19 Update: Baricitinib (Olumiant) FDA-Approved for Treatment of COVID-19 (online only)

The FDA has approved the oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) for treatment of COVID-19 in hospitalized adults who require supplemental oxygen, mechanical ventilation, or extracorporeal…

Med Lett Drugs Ther. 2022 Jun 13; 64(1652):e2-3
The FDA has approved the oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) for treatment of COVID-19 in hospitalized adults who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Baricitinib was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for use in children 2-17 years old hospitalized with COVID-19 who require oxygen support.
Issue 1637 · November 15, 2021
Drugs for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were…

Med Lett Drugs Ther. 2021 Nov 15; 63(1637):177-84
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Issue 1637 · November 15, 2021
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)

View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis

Med Lett Drugs Ther. 2021 Nov 15; 63(1637):e187-9
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Issue 1637 · November 15, 2021
Flowchart: Rheumatoid Arthritis Treatment (online only)

View the Flowchart: Rheumatoid Arthritis Treatment

Med Lett Drugs Ther. 2021 Nov 15; 63(1637):e1
View the Flowchart: Rheumatoid Arthritis Treatment
Issue 1634 · October 4, 2021 Free
In Brief: New Warnings for Janus Kinase Inhibitors

The FDA has required updates to the boxed warnings in the labeling of the Janus kinase (JAK) inhibitors tofacitinib (Xeljanz, Xeljanz XR) , baricitinib (Olumiant ), and upadacitinib (Rinvoq) describing…

Med Lett Drugs Ther. 2021 Oct 4; 63(1634):160
The FDA has required updates to the boxed warnings in the labeling of the Janus kinase (JAK) inhibitors tofacitinib (Xeljanz, Xeljanz XR) , baricitinib (Olumiant ), and upadacitinib (Rinvoq) describing increased risks of major adverse cardiovascular events, malignancy, thrombosis, and death with their use. The new warnings were prompted by the results of a postmarketing safety trial with tofacitinib and were added to the labels of baricitinib and upadacitinib based on the presumption of a class effect. The tofacitinib package insert had contained a boxed warning about an increased risk of thrombosis and mortality with a dosage of 10 mg twice daily since 2019, but the new warnings are not limited by dose.
Issue 1629 · July 26, 2021 Free
An EUA for Tocilizumab (Actemra) for COVID-19

The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):113-4
The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years old who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab has been approved by the FDA for various indications, including rheumatoid arthritis and juvenile idiopathic arthritis.
Issue 1614 · December 28, 2020 Free
An EUA for Baricitinib (Olumiant) for COVID-19

The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2…

Med Lett Drugs Ther. 2020 Dec 28; 62(1614):202-3
The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2 years old who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); the EUA requires that baricitinib be used in combination with the IV antiviral drug remdesivir (Veklury) . Baricitinib has been available for treatment of rheumatoid arthritis since 2018. Remdesivir was recently approved by the FDA for treatment of COVID-19 in hospitalized patients ≥12 years old who weigh ≥40 kg; it is available under an EUA for treatment of other hospitalized patients.
Issue 1600 · June 15, 2020
Drugs for Atopic Dermatitis

Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2020 Jun 15; 62(1600):89-96
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Issue 1595 · April 6, 2020 Free
Table: Treatments Considered for COVID-19 (Archived) (online only)

View the Table: Treatments Considered for COVID-19

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):e1-289
View the Table: Treatments Considered for COVID-19
Issue 1585 · November 18, 2019
Upadacitinib (Rinvoq) - A New JAK Inhibitor for Rheumatoid Arthritis

The FDA has approved upadacitinib ( Rinvoq – Abbvie), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate…

Med Lett Drugs Ther. 2019 Nov 18; 61(1585):183-5
The FDA has approved upadacitinib ( Rinvoq – Abbvie), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to or cannot tolerate methotrexate ( Trexall , and others). Upadacitinib is the third JAK inhibitor to be approved in the US for treatment of RA; tofacitinib (Xeljanz, Xeljanz XR) and baricitinib (Olumiant) were approved earlier.
Issue 1579 · August 26, 2019 Free
In Brief: Risk of Pulmonary Thromboembolism and Death with Tofacitinib (Xeljanz)

The FDA has required updates to the labeling of the Janus kinase (JAK) inhibitor tofacitinib (Xeljanz, Xeljanz XR) based on interim results of a postmarketing safety trial that showed an increased risk of…

Med Lett Drugs Ther. 2019 Aug 26; 61(1579):136
The FDA has required updates to the labeling of the Janus kinase (JAK) inhibitor tofacitinib (Xeljanz, Xeljanz XR) based on interim results of a postmarketing safety trial that showed an increased risk of pulmonary thromboembolism and death with a dosage of 10 mg twice daily. 1 Tofacitinib is approved for treatment of rheumatoid arthritis (RA), 2 psoriatic arthritis, and ulcerative colitis. In the postmarketing trial, RA patients ≥50 years old taking methotrexate who had at least one cardiovascular risk factor were randomized to receive add-on treatment with tofacitinib 5 mg twice daily (the FDA-approved dosage for RA and psoriatic arthritis), tofacitinib 10 mg twice daily (an approved dosage for ulcerative colitis), or a tumor necrosis factor (TNF) inhibitor. At the time of the interim analysis in January 2019 (~3900 patient-years of data in each group), pulmonary thromboembolism had occurred in 19 patients taking tofacitinib 10 mg twice daily and in 3 patients taking a TNF inhibitor; 45 patients taking tofacitinib 10 mg twice daily and 25 taking a TNF inhibitor had died. Interim data from the 5-mg twice daily group have not been made available by the FDA. After the interim analysis, patients taking the higher dose of tofacitinib were transitioned into the 5 mg twice daily group; the trial is ongoing. 3 Serious, sometimes fatal thromboembolic adverse events have also occurred with use of baricitinib (Olumiant) , 4 another JAK inhibitor that is FDA-approved for treatment of RA. Whether an increased risk of thromboembolism is a class effect of JAK inhibitors remains to be determined; RA itself has been associated with an increased thromboembolic risk. 5 The tofacitinib package insert now contains a boxed warning describing the increased risk of thrombosis and mortality with a dosage of 10 mg twice daily and emphasizes that this dosage or Xeljanz XR 22 mg once daily is not recommended for treatment of RA or psoriatic arthritis. For treatment of ulcerative colitis, tofacitinib is now only indicated in patients who have had an inadequate response or intolerance to TNF inhibitors; for these patients, the 10-mg twice daily dosage is still recommended as induction therapy for 8 weeks (can be continued for up to 16 weeks) and for maintenance treatment when there is loss of response to a dosage of 5 mg twice daily. FDA drug safety communication: FDA approves boxed warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). July 26, 2019. Available at: www.fda.gov. Accessed August 15, 2019. Tofacitinib for rheumatoid arthritis. Med Lett Drugs Ther 2013; 55:1. FDA drug safety communication: Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate. February 25, 2019. Available at: https://www.fda.gov. Accessed August 15, 2019. Baricitinib (Olumiant) for rheumatoid arthritis. Med Lett Drugs Ther 2018; 60:120. IC Scott et al. Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf 2018; 41:645. Download complete U.S. English article
Issue 1552 · July 30, 2018
Drugs for Rheumatoid Arthritis

Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally do…

Med Lett Drugs Ther. 2018 Jul 30; 60(1552):123-8
Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally do not have an immediate analgesic effect, but over time they can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate ( Trexall , and others) is generally the drug of choice; it can be used for patients with low, moderate, or high disease activity. For mild disease, some clinicians prefer to start with hydroxychloroquine ( Plaquenil , and generics) and/or sulfasalazine ( Azulfidine , and others).
Issue 1552 · July 30, 2018
Expanded Table: Biologic Agents for Rheumatoid Arthritis (online only)

View Expanded Table: Biologic Agents for Rheumatoid Arthritis

Med Lett Drugs Ther. 2018 Jul 30; 60(1552):e130-4
View Expanded Table: Biologic Agents for Rheumatoid Arthritis
Issue 1551 · July 16, 2018
Baricitinib (Olumiant) for Rheumatoid Arthritis

The FDA has approved the Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) for oral treatment of adults with moderately to severely active rheumatoid arthritis (RA) that has not responded…

Med Lett Drugs Ther. 2018 Jul 16; 60(1551):120-1
The FDA has approved the Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) for oral treatment of adults with moderately to severely active rheumatoid arthritis (RA) that has not responded adequately to one or more tumor necrosis factor (TNF) inhibitors. Baricitinib is the second JAK inhibitor to be approved for treatment of RA; tofacitinib (Xeljanz, Xeljanz XR) was the first.